| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910495781103321 |
|
|
Autore |
Borrel Pascale |
|
|
Titolo |
Défier la décence : Crise du sens et nouveaux visages du scandale dans l’art / / Leszek Brogowski, Joseph Delaplace, Joël Laurent |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Arras, : Artois Presses Université, 2020 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (264 p.) |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Altri autori (Persone) |
|
BraunPierre |
BrogowskiLeszek |
CauchySéverine |
DaniellouSimon |
DelaplaceJoseph |
DufeuFrédéric |
DupeyratJérôme |
ÉlisabethBruno |
FerretSandrine |
HénaffGaël |
LaurentJoël |
LouvelRomain |
NaessensOphélie |
PageChristiane |
RabinJulien |
TrichetYohan |
|
|
|
|
|
|
|
|
Soggetti |
|
Art |
art |
morale |
obscénité dans l’art |
scandale artistique |
ordre social |
industrie culturelle |
média |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Les scandales de l’art moderne prouvaient que celui-ci alimentait secrètement le registre du sens, lié à la symbolisation de l’ordre social. Mais aujourd’hui, la société a définitivement abandonné l’idée de l’art comme langage universel, et, pour ne plus craindre les troubles causés par des œuvres ou des artistes, elle a confié à l’industrie culturelle le soin de mettre la main sur les symboles et d’en distiller cyniquement les bouleversements. Le présent ouvrage tâche de relever le défi de repenser le scandale dans ce nouveau contexte. La crédibilité de la presse à porter les expressions spontanées des sentiments populaires étant définitivement compromise, le scandale semble se réfugier dans des formes moins spectaculaires et plus attentives au travail du sens, et à ses crises latentes. Défier la décence propose l’étude de diverses situations contribuant notamment aux mouvements actuels de l’art (œuvres, spectacles, concerts, mais aussi manifestes, modes de vie et de comportements, controverses juridiques, inspirations scientifiques, etc.), comme catalyseurs ou révélateurs des crises, indissociablement artistiques et politiques, parfois sans le moindre écho dans les mass-media. |
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910674051103321 |
|
|
Autore |
Collin Rob W.J |
|
|
Titolo |
Molecular Therapies for Inherited Retinal Diseases |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
|
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (262 p.) |
|
|
|
|
|
|
Soggetti |
|
Biology, life sciences |
Research & information: general |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Following the implementation of next-generation sequencing technologies (e.g., exome and genome sequencing) in molecular |
|
|
|
|
|
|
|
|
|
|
diagnostics, the majority of genetic defects underlying inherited retinal disease (IRD) can readily be identified. In parallel, opportunities to counteract the molecular consequences of these defects are rapidly emerging, providing hope for personalized medicine. 'Classical' gene augmentation therapy has been under study for several genetic subtypes of IRD and can be considered a safe and sometimes effective therapeutic strategy. The recent market approval of the first retinal gene augmentation therapy product (LuxturnaTM, for individuals with bi-allelic RPE65 mutations) by the FDA has not only demonstrated the potential of this specific approach, but also opened avenues for the development of other strategies. However, every gene-or even every mutation-may need a tailor-made therapeutic approach, in order to obtain the most efficacious strategy with minimal risks associated. In addition to gene augmentation therapy, other subtypes of molecular therapy are currently being designed and/or implemented, including splice modulation, DNA or RNA editing, optogenetics and pharmacological modulation. In addition, the development of proper delivery vectors has gained strong attention, and should not be overlooked when designing and testing a novel therapeutic approach. In this Special Issue, we aim to describe the current state of the art of molecular therapeutics for IRD, and discuss existing and novel therapeutic strategies, from idea to implementation, and from bench to bedside. |
|
|
|
|
|
| |